Contributor: MFM Division
Last Update: 12/15/2010
Screening for GC in pregnancy is recommended because it may:
- Have deleterious effects on pregnancy in any trimester (miscarriage, preterm delivery, chorioamnionitis, postpartum infection)
- Become disseminated and result in serious systemic infection
- Cause neonatal ophthalmia or systemic disease
- Often be asymptomatic in females
A cervical specimen for GC testing should be obtained at the first prenatal examination. It should be repeated in the third trimester if there is a history of an STD. In addition, GC and Chlamydia testing should be performed on women in PTL, if a culture has not be done in the past 4 weeks.
Culture, nucleic acid hybridization tests and nucleic acid amplification tests (NAAT) are available for the detection of genitourinary infection with N. gonorrhoeae. If sensitivity testing is needed, a culture must be requested.
First line therapy for uncomplicated GC cervicitis is Ceftriaxone 125 mg IM in a single dose. Alternate regimens include Cefixime 400 mg orally in a single dose, and, for patients who cannot tolerate a cephalosporin, Spectinomycin 2 gm IM in a single dose.
Repeat testing to insure effective treatment for GC infection is recommended after therapy is complete. The sexual partners of women diagnosed with GC should be referred to the Health Department or a primary care MD for treatment and sexual intercourse avoided until the issue of infection is resolved.
1. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2006. Available at: https://www.cdc.gov.